10 December 2020 - Prophylaxis study
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19
et al., Diabetes & Metabolism, doi:10.1016/j.diabet.2020.101216 (Peer Reviewed)
Retrospective 2,449 hospitalized COVID-19 diabetes patients in France, 1,496 with existing metformin use, showing lower mortality with treatment. Statistical significance was reached in model 1 but not in models 2-4 which also adjust for HbA1c, eGFR, and diabetes duration, but have a lower number of patients. CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes).
|
risk of death, 22.2% lower, RR 0.78, p = 0.16, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
|
|
risk of death/intubation, 17.8% lower, RR 0.82, p = 0.21, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
|
|
risk of mechanical ventilation, 6.8% lower, RR 0.93, p = 0.72, treatment 671, control 419, day 28, model 2, propensity score matching, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Lalau et al., 12/10/2020, retrospective, France, Europe, peer-reviewed, 33 authors, study period 10 March, 2020 - 10 April, 2020.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.